Titan Partners acted as sole book running manager for the offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALRN:
- Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
- Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
- Aileron Therapeutics price target raised to $19 from $9 at Ladenburg
- Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Aileron Therapeutics Announces CFO Transition and Appointment